Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 232

1.

Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial.

Ducourau E, Rispens T, Samain M, Dernis E, Le Guilchard F, Andras L, Perdriger A, Lespessailles E, Martin A, Cormier G, Armingeat T, Devauchelle-Pensec V, Gervais E, Le Goff B, de Vries A, Piver E, Paintaud G, Desvignes C, Ternant D, Watier H, Goupille P, Mulleman D.

RMD Open. 2020 Jan;6(1). pii: e001047. doi: 10.1136/rmdopen-2019-001047. Epub 2020 Jan 9.

2.

[Biosimilars antibodies: positioning compared to originators - the experience in rheumatology and the biosimilars of trastuzumab in oncology].

Pivot X, Goupille P.

Med Sci (Paris). 2019 Dec;35(12):1137-1145. doi: 10.1051/medsci/2019214. Epub 2020 Jan 6. French.

PMID:
31903928
3.

Practical management of patients on Janus kinase inhibitor (JAKi) therapy: Practical fact sheets drawn up by the Rheumatism and Inflammation Club (CRI), a group endorsed by the French Society for Rheumatology (SFR).

Richez C, Morel J, Cornec D, Daïen C, Goupille P, Lazaro E, Lequerré T, Nocturne G, de Lédinghen V, Le Goff B, Pourcher V, Prati C, Seror R, Tournadre A, Truchetet ME, Sibilia J, Pham T.

Joint Bone Spine. 2019 Oct;86 Suppl 1:eS2-eS103. doi: 10.1016/S1297-319X(19)30154-X. Epub 2019 Oct 31. No abstract available.

PMID:
31791545
4.

A Comparative Study of Fibromyalgia, Rheumatoid Arthritis, Spondyloarthritis, and Sjögren's Syndrome; Impact of the Disease on Quality of Life, Psychological Adjustment, and Use of Coping Strategies.

Bucourt E, Martaillé V, Goupille P, Joncker-Vannier I, Huttenberger B, Réveillère C, Mulleman D, Courtois AR.

Pain Med. 2019 Nov 9. pii: pnz255. doi: 10.1093/pm/pnz255. [Epub ahead of print]

PMID:
31710690
5.

Baseline MRI inflammation is not a determinant of 5-year bone mineral density loss in patients with early spondyloarthritis.

Fechtenbaum M, Molto A, Roux C, Goupille P, Chevret S, Briot K.

Joint Bone Spine. 2020 Jan;87(1):63-68. doi: 10.1016/j.jbspin.2019.09.016. Epub 2019 Oct 11.

PMID:
31606496
6.

CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis.

Bensalem A, Mulleman D, Thibault G, Azzopardi N, Goupille P, Paintaud G, Ternant D.

Br J Clin Pharmacol. 2019 Dec;85(12):2747-2758. doi: 10.1111/bcp.14102. Epub 2019 Nov 22.

PMID:
31454097
7.

Drug maintenance of a second tumor necrosis factor alpha inhibitor in spondyloarthritis patients: A real-life multicenter study.

Krajewski F, Andras L, Pereira-Gillion C, Goupille P, Salliot C.

Joint Bone Spine. 2019 Nov;86(6):761-767. doi: 10.1016/j.jbspin.2019.07.003. Epub 2019 Jul 18.

PMID:
31326602
8.

Evaluation of the performances of 'typical' imaging abnormalities of axial spondyloarthritis: results of the cross-sectional ILOS-DESIR study.

Molto A, Gossec L, Lefèvre-Colau MM, Foltz V, Beaufort R, Laredo JD, Richette P, Dieude P, Goupille P, Feydy A, Dougados M.

RMD Open. 2019 May 28;5(1):e000918. doi: 10.1136/rmdopen-2019-000918. eCollection 2019.

9.

Measuring spinal mobility in early axial spondyloarthritis: does it matter?

Marques ML, Ramiro S, Goupille P, Dougados M, van Gaalen F, van der Heijde D.

Rheumatology (Oxford). 2019 Sep 1;58(9):1597-1606. doi: 10.1093/rheumatology/kez026.

PMID:
30879078
10.

[Aphthous mouth ulcers as an initial manifestation of sécukinumab-induced inflammatory bowel disease].

Grimaux X, Leducq S, Goupille P, Aubourg A, Miquelestorena-Standley E, Samimi M.

Ann Dermatol Venereol. 2018 Nov;145(11):676-682. doi: 10.1016/j.annder.2018.07.009. Epub 2018 Oct 23. French.

PMID:
30366718
11.

Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials.

Mease P, Roussou E, Burmester GR, Goupille P, Gottlieb A, Moriarty SR, Benichou O, Adams DH, Xu W, Nash P.

Arthritis Care Res (Hoboken). 2019 Mar;71(3):367-378. doi: 10.1002/acr.23738. Epub 2019 Feb 12.

12.

Determinants of daily pain trajectories and relationship with pain acceptability in hip and knee osteoarthritis. A national prospective cohort study on 886 patients.

Trouvin AP, Marty M, Goupille P, Perrot S.

Joint Bone Spine. 2019 Mar;86(2):245-250. doi: 10.1016/j.jbspin.2018.06.009. Epub 2018 Jul 17.

PMID:
30025954
13.

Application of Recommendations Regarding the Use of Subcutaneous Tumor Necrosis Factor Inhibitors in Spondyloarthritis by Rheumatologists in Daily Practice.

Pereira-Gillion C, Marot M, Griffoul-Espitalier I, Andras L, Goupille P, Salliot C.

J Rheumatol. 2018 Apr;45(4):491-497. doi: 10.3899/jrheum.170587. Epub 2018 Feb 1.

PMID:
29419472
14.

2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis.

Wendling D, Lukas C, Prati C, Claudepierre P, Gossec L, Goupille P, Hudry C, Miceli-Richard C, Molto A, Pham T, Saraux A, Dougados M.

Joint Bone Spine. 2018 May;85(3):275-284. doi: 10.1016/j.jbspin.2018.01.006. Epub 2018 Mar 8. Review.

PMID:
29407043
15.

Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration.

Ternant D, Passot C, Aubourg A, Goupille P, Desvignes C, Picon L, Lecomte T, Mulleman D, Paintaud G.

Clin Pharmacokinet. 2018 Sep;57(9):1173-1184. doi: 10.1007/s40262-017-0621-6.

PMID:
29236229
16.

Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatoid Arthritis.

Medina F, Plasencia C, Goupille P, Ternant D, Balsa A, Mulleman D.

Ther Drug Monit. 2017 Aug;39(4):364-369. doi: 10.1097/FTD.0000000000000421. Review.

PMID:
28700520
17.

High incidence of vertebral osteoporotic fracture within the first year after liver transplantation.

Butin S, Griffoul I, Espitalier F, Salamé E, Mulleman D, Goupille P.

Clin Exp Rheumatol. 2017 Nov-Dec;35(6):913-918. Epub 2017 Apr 29.

PMID:
28516878
18.

Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Spondyloarthritis.

Medina F, Plasencia C, Goupille P, Paintaud G, Balsa A, Mulleman D.

Ther Drug Monit. 2017 Aug;39(4):360-363. doi: 10.1097/FTD.0000000000000400. Review.

PMID:
28379895
19.

Repeated decrease of CD4+ T-cell counts in patients with rheumatoid arthritis over multiple cycles of rituximab treatment.

Lavielle M, Mulleman D, Goupille P, Bahuaud C, Sung HC, Watier H, Thibault G.

Arthritis Res Ther. 2016 Oct 28;18(1):253.

20.

The underlying inflammatory chronic disease influences infliximab pharmacokinetics.

Passot C, Mulleman D, Bejan-Angoulvant T, Aubourg A, Willot S, Lecomte T, Picon L, Goupille P, Paintaud G, Ternant D.

MAbs. 2016 Oct;8(7):1407-1416. Epub 2016 Aug 9.

21.

Comparison of the Big Five personality traits in fibromyalgia and other rheumatic diseases.

Bucourt E, Martaillé V, Mulleman D, Goupille P, Joncker-Vannier I, Huttenberger B, Reveillere C, Courtois R.

Joint Bone Spine. 2017 Mar;84(2):203-207. doi: 10.1016/j.jbspin.2016.03.006. Epub 2016 Jun 3.

PMID:
27269650
22.

TNFα antagonist therapy in axial spondyloarthritis: Can we do better?

Prati C, Claudepierre P, Goupille P, Pham T, Wendling D.

Joint Bone Spine. 2016 May;83(3):247-9. doi: 10.1016/j.jbspin.2016.01.004. Epub 2016 Feb 10. No abstract available.

PMID:
26875066
23.

[Immunogenicity of biopharmaceuticals: Which consequences during the treatment of rheumatoid arthritis?].

Goupille P.

Rev Med Interne. 2016 May;37(5):343-9. doi: 10.1016/j.revmed.2015.09.014. Epub 2015 Oct 31. Review. French.

PMID:
26526777
24.

Increase in Dickkopf-1 Serum Level in Recent Spondyloarthritis. Data from the DESIR Cohort.

Nocturne G, Pavy S, Boudaoud S, Seror R, Goupille P, Chanson P, van der Heijde D, van Gaalen F, Berenbaum F, Mariette X, Briot K, Feydy A, Claudepierre P, Dieudé P, Nithitham J, Taylor KE, Criswell LA, Dougados M, Roux C, Miceli-Richard C.

PLoS One. 2015 Aug 27;10(8):e0134974. doi: 10.1371/journal.pone.0134974. eCollection 2015.

25.

Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: The DESIR cohort.

Dougados M, Etcheto A, Molto A, Alonso S, Bouvet S, Daurès JP, Landais P, d'Agostino MA, Berenbaum F, Breban M, Claudepierre P, Combe B, Fautrel B, Feydy A, Goupille P, Richette P, Pham T, Roux C, Treluyer JM, Saraux A, van der Heijde D, Wendling D; DESIR cohort.

Joint Bone Spine. 2015 Oct;82(5):345-51. doi: 10.1016/j.jbspin.2015.02.006. Epub 2015 Jul 16.

PMID:
26190454
26.

F-18 fluorodeoxyglucose positron emission tomography can detect early response to adalimumab, a tumor necrosis factor-α antagonist, in rheumatoid arthritis: A prospective pilot study.

Edupuganti SR, Eder V, Ternant D, Courtehoux M, Tranquart F, Goupille P, Paintaud G, Mulleman D.

Joint Bone Spine. 2015 Oct;82(5):381-3. doi: 10.1016/j.jbspin.2015.01.014. Epub 2015 Mar 13. No abstract available.

PMID:
25776440
27.

Management of osteoporosis in women after forearm fracture: data from a French health insurance database.

Erny F, Auvinet A, Chu Miow Lin D, Pioger A, Haguenoer K, Tauveron P, Jacquot F, Rusch E, Goupille P, Mulleman D.

Joint Bone Spine. 2015 Jan;82(1):52-5. doi: 10.1016/j.jbspin.2014.07.007. Epub 2014 Sep 17.

PMID:
25241339
28.

Psychological distress over time in early rheumatoid arthritis: results from a longitudinal study in an early arthritis cohort.

Bacconnier L, Rincheval N, Flipo RM, Goupille P, Daures JP, Boulenger JP, Combe B.

Rheumatology (Oxford). 2015 Mar;54(3):520-7. doi: 10.1093/rheumatology/keu371. Epub 2014 Sep 14.

PMID:
25224416
29.

Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.

Ternant D, Ducourau E, Fuzibet P, Vignault C, Watier H, Lequerré T, Le Loët X, Vittecoq O, Goupille P, Mulleman D, Paintaud G.

Br J Clin Pharmacol. 2015 Feb;79(2):286-97. doi: 10.1111/bcp.12509.

30.

Association of anticyclic citrullinated peptide antibodies and/or rheumatoid factor status and clinical presentation in early arthritis: results from the ESPOIR cohort.

Mouterde G, Lukas C, Goupille P, Flipo RM, Rincheval N, Daurès JP, Combe B.

J Rheumatol. 2014 Aug;41(8):1614-22. doi: 10.3899/jrheum.130884. Epub 2014 Jul 15.

PMID:
25028372
31.

Towards an individualised target concentration of adalimumab in rheumatoid arthritis.

Ducourau E, Ternant D, Lequerré T, Fuzibet P, Le Loët X, Watier H, Goupille P, Paintaud G, Vittecoq O, Mulleman D.

Ann Rheum Dis. 2014 Jul;73(7):1428-9. doi: 10.1136/annrheumdis-2013-204971. Epub 2014 Feb 18. No abstract available.

PMID:
24550169
32.

Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis.

Wendling D, Lukas C, Paccou J, Claudepierre P, Carton L, Combe B, Goupille P, Guillemin F, Hudry C, Miceli-Richard C, Dougados M; French Society for Rheumatology (SFR).

Joint Bone Spine. 2014 Jan;81(1):6-14. doi: 10.1016/j.jbspin.2013.12.002. Epub 2014 Jan 10.

33.

Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis.

Ternant D, Ducourau E, Perdriger A, Corondan A, Le Goff B, Devauchelle-Pensec V, Solau-Gervais E, Watier H, Goupille P, Paintaud G, Mulleman D.

Br J Clin Pharmacol. 2014 Jul;78(1):118-28. doi: 10.1111/bcp.12313.

34.

Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.

Combe B, Rincheval N, Benessiano J, Berenbaum F, Cantagrel A, Daurès JP, Dougados M, Fardellone P, Fautrel B, Flipo RM, Goupille P, Guillemin F, Le Loët X, Logeart I, Mariette X, Meyer O, Ravaud P, Saraux A, Schaeverbeke T, Sibilia J.

J Rheumatol. 2013 Oct;40(10):1650-7. doi: 10.3899/jrheum.121515. Epub 2013 Aug 15.

PMID:
23950185
35.

Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response.

Mélet J, Mulleman D, Goupille P, Ribourtout B, Watier H, Thibault G.

Arthritis Rheum. 2013 Nov;65(11):2783-90. doi: 10.1002/art.38107.

36.

Better reporting and greater homogeneity in outcome measures are seen in randomized trial protocols when guidelines exist.

Sautenet B, Caille A, Halimi JM, Goupille P, Giraudeau B.

J Clin Epidemiol. 2013 Aug;66(8):838-46. doi: 10.1016/j.jclinepi.2013.03.015.

PMID:
23810024
37.

Intra-articular hylastan versus steroid for knee osteoarthritis.

Housman L, Arden N, Schnitzer TJ, Birbara C, Conrozier T, Skrepnik N, Wei N, Bockow B, Waddell D, Tahir H, Hammond A, Goupille P, Sanson BJ, Elkins C, Bailleul F.

Knee Surg Sports Traumatol Arthrosc. 2014 Jul;22(7):1684-92. doi: 10.1007/s00167-013-2438-7. Epub 2013 Feb 16.

PMID:
23417236
38.

[Persistent aphthous mouth ulcers associated with tocilizumab: two cases].

Samimi M, Lauferon F, Hüttenberger B, Vaillant L, Goupille P, Machet L.

Ann Dermatol Venereol. 2013 Feb;140(2):120-4. doi: 10.1016/j.annder.2012.11.006. Epub 2012 Dec 25. French.

PMID:
23395494
39.

Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.

Gottenberg JE, Cinquetti G, Larroche C, Combe B, Hachulla E, Meyer O, Pertuiset E, Kaplanski G, Chiche L, Berthelot JM, Gombert B, Goupille P, Marcelli C, Feuillet S, Leone J, Sibilia J, Zarnitsky C, Carli P, Rist S, Gaudin P, Salliot C, Piperno M, Deplas A, Breban M, Lequerre T, Richette P, Ghiringhelli C, Hamidou M, Ravaud P, Mariette X; Club Rhumatismes et Inflammations and the French Society of Rheumatology.

Ann Rheum Dis. 2013 Jun;72(6):1026-31. doi: 10.1136/annrheumdis-2012-202293. Epub 2012 Dec 21.

PMID:
23264337
40.

Prediction of radiographic damage in early arthritis by sonographic erosions and power Doppler signal: a longitudinal observational study.

Funck-Brentano T, Gandjbakhch F, Etchepare F, Jousse-Joulin S, Miquel A, Cyteval C, Lukas C, Tobón GJ, Saraux A, Boumier P, Goupille P, Bourgeois P, Fautrel B.

Arthritis Care Res (Hoboken). 2013 Jun;65(6):896-902. doi: 10.1002/acr.21912.

41.

Predictive factors for development of neck pain among computer users.

Zomalheto Z, Goupille P, Gounongbe M, Avimadje M.

Joint Bone Spine. 2012 Dec;79(6):632-3. doi: 10.1016/j.jbspin.2012.06.001. Epub 2012 Jul 12. No abstract available.

PMID:
22795328
42.

Abatacept therapy and safety management.

Pham T, Bachelez H, Berthelot JM, Blacher J, Claudepierre P, Constantin A, Fautrel B, Gaujoux-Viala C, Goëb V, Gossec L, Goupille P, Guillaume-Czitrom S, Hachulla E, Lequerré T, Marolleau JP, Martinez V, Masson C, Mouthon L, Puéchal X, Richette P, Saraux A, Schaeverbeke T, Soubrier M, Viguier M, Vittecoq O, Wendling D, Mariette X, Sibilia J.

Joint Bone Spine. 2012 Mar;79 Suppl 1:3-84. doi: 10.1016/S1297-319X(12)70011-8.

PMID:
22541956
43.

Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? A multicentre retrospective observational study.

Lekpa FK, Poulain C, Wendling D, Soubrier M, De Bandt M, Berthelot JM, Gaudin P, Toussirot E, Goupille P, Pham T, Sellam J, Bruckert R, Paul M, Farrenq V, Claudepierre P; Club Rhumatismes et Inflammation.

Arthritis Res Ther. 2012 Mar 9;14(2):R53.

44.

Should anti-TNF-α drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis?

Mulleman D, Ducourau E, Paintaud G, Ternant D, Watier H, Goupille P.

Joint Bone Spine. 2012 Mar;79(2):109-12. doi: 10.1016/j.jbspin.2011.11.004. Epub 2012 Feb 20. No abstract available.

PMID:
22356754
45.

Factors associated with fatigue in early arthritis: results from a multicenter national French cohort study.

Rat AC, Pouchot J, Fautrel B, Boumier P, Goupille P, Guillemin F.

Arthritis Care Res (Hoboken). 2012 Jul;64(7):1061-9. doi: 10.1002/acr.21647.

46.

Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.

Mariette X, Baron G, Tubach F, Lioté F, Combe B, Miceli-Richard C, Flipo RM, Goupille P, Allez M, Salmon D, Emilie D, Carcelain G, Ravaud P.

Ann Rheum Dis. 2012 Nov;71(11):1783-90. doi: 10.1136/annrheumdis-2011-200408. Epub 2012 Jan 17.

PMID:
22258485
47.

Therapeutic drug monitoring of infliximab in spondyloarthritis: an observational open-label study.

Méric JC, Mulleman D, Ducourau E, Lauféron F, Miow Lin DC, Watier H, Goupille P, Paintaud G.

Ther Drug Monit. 2011 Aug;33(4):411-6. doi: 10.1097/FTD.0b013e318224f83d.

PMID:
21743380
48.

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases.

Ducourau E, Mulleman D, Paintaud G, Miow Lin DC, Lauféron F, Ternant D, Watier H, Goupille P.

Arthritis Res Ther. 2011 Jun 27;13(3):R105. doi: 10.1186/ar3386.

49.

TNF alpha antagonist therapy and safety monitoring.

Pham T, Bachelez H, Berthelot JM, Blacher J, Bouhnik Y, Claudepierre P, Constantin A, Fautrel B, Gaudin P, Goëb V, Gossec L, Goupille P, Guillaume-Czitrom S, Hachulla E, Huet I, Jullien D, Launay O, Lemann M, Maillefert JF, Marolleau JP, Martinez V, Masson C, Morel J, Mouthon L, Pol S, Puéchal X, Richette P, Saraux A, Schaeverbeke T, Soubrier M, Sudre A, Tran TA, Viguier M, Vittecoq O, Wendling D, Mariette X, Sibilia J.

Joint Bone Spine. 2011 May;78 Suppl 1:15-185. doi: 10.1016/S1297-319X(11)70001-X.

PMID:
21703545
50.

[Recommendations on the management of psoriatic arthritis].

Passeron T, Goupille P, Boulinguez S.

Ann Dermatol Venereol. 2011 Jun;138(6 Suppl 1):H10-2. doi: 10.1016/S0151-9638(11)70062-X. French. No abstract available.

PMID:
21703468

Supplemental Content

Loading ...
Support Center